/** blogpostTitle: Torrent Pharma Q1 FY27: JB integration lifts scale, semaglutide hits a supply bump blogpostSlug: torrent-q1fy27 blogpostCoverImageUrl: null blogpostCoverImageDescription: Ultra-realistic corporate finance scene showing a clean dashboard on a large monitor with a rising revenue bar chart and an EBITDA margin gauge near one-third, alongside smaller panels indicating India, Brazil, US, and Germany performance; a second subtle overlay shows an integration timeline progressing into the next 2 to 3 quarters and a small warning icon near an injectable supply line, all in a modern boardroom setting with neutral lighting and no text labels or logos. blogpostShortTitle: Torrent Pharma Q1 FY27 integration update */

Torrent Pharma Q1 FY27: JB integration lifts scale, semaglutide hits a supply bump

Torrent Pharmaceuticals reported a sharp step-up in scale in Q1 FY27, the first quarter around the completion of the merger of JB with Torrent (effective July 8, 2026; appointed date January 21, 2026). Consolidated revenue came in at INR4,921 crore, up 55% year-on-year. Operating EBITDA rose 61% to INR1,664 crore, taking the operating EBITDA margin to 33.8%.

The quarter’s narrative had three distinct threads. First, the financials benefited from combining two profitable India-focused franchises. Second, management signalled that cost synergies are landing faster than originally expected. Third, a high-profile India launch in semaglutide saw an unexpected but temporary supply disruption on the injectable side, creating near-term noise while management remains focused on retaining leadership.

What the quarter looked like across the combined business

Management discussed performance in two parts: the “underlying JB business” and the “Torrent base business.” JB’s underlying Q1 revenue was INR1,201 crore, up 10% year-on-year, with operating EBITDA of INR424 crore and EBITDA margin of 35.3%. Torrent’s base business delivered 17% revenue growth for the quarter, with operating EBITDA of INR1,240 crore, up 20%, and margins at 33.3%.

India remained the core engine. Torrent’s India base business revenue for Q1 was INR2,157 crore, growing 19% versus IPM growth of 12% as per AIOCD Pharmatrac. Management attributed the outperformance to a better IPM growth environment, strong new launch performance, and volume growth acceleration linked to field-force expansion.

Outside India, performance was mixed by geography. Brazil saw strong underlying demand momentum, while Germany continued to face challenges. The US generics business showed growth, though management noted that part of the uplift included one-time opportunities.

JB integration: cost synergies now the headline

The most debated datapoint in the call was JB’s margin print. When asked whether the 35% plus EBITDA margin was driven by CDMO operating leverage or by synergies, management’s answer was clear: the improvement was largely due to cost synergies being implemented sooner than expected. While operating leverage may have helped at the margin, the primary driver was synergy execution.

Management did not publish a revised synergy target, but did acknowledge that the first-year synergy number would exceed the earlier INR90 crore expectation. They stated it is “definitely going to be above 100” crore, while refraining from providing an exact figure because some territories may see minor and transient revenue impact during ongoing integration work.

This is an important nuance. The company is not presenting synergy capture as a one-off event. Instead, it is framing it as a process that should keep improving quarter-on-quarter, with some reinvestment back into the business depending on territory-level needs.

The integration plan now moves into a more operational phase. In India, Torrent has started merging certain brands and divisions from JB into Torrent post the merger. Management noted that in past acquisitions, brand transfers can create a brief transition impact as field teams change and prescriber relationships get rebuilt, even when the transfer process is executed carefully. The expectation is for this to be minor and temporary, and for business momentum to normalize by Q4 FY27.

On the international side of JB, management mentioned portfolio rationalisation in certain territories, focusing on lower-margin and lower-priority products to enable network optimisation. They described this as conceptually similar to what Torrent did earlier in India trade generics.

India: outperformance, Curatio momentum, and semaglutide disruption

India delivered one of the strongest parts of the quarter. The company highlighted multiple operating indicators: combined field-force strength stood at 9,400 at the end of Q1, with 7,200 in the base business and 2,200 in JB. Combined PCPM was just over INR10 lakhs, and management sees scope for further improvement.

Curatio continued to scale rapidly. The Curatio business grew 34% in Q1, driven by OTC advertising spends and field-force expansion. Management said it is undertaking further field-force expansion in Curatio during FY27, given the positive outcomes so far.

Another milestone was in chronic therapies. Management stated that Torrent with JB now ranks first in the cardiac market, which it described as the largest and among the fastest-growing markets in the Indian pharma market.

Semaglutide was the quarter’s most visible product story. Management reported that its semaglutide franchise in India recorded a Q1 market share of 36% for oral and injectable combined as per Pharmatrac. Even with one more competitor entering the oral market, it said it held 94% market share in June.

However, an unforeseen supply-related issue at the manufacturing partner for the injectable product disrupted availability. Management said it has secured an alternate supply source and expects all Semalix SKUs to be back in the market by end-August. It also clarified that the issue does not impact oral brands or the reusable SKU.

The financial impact is near-term. Management said there will be loss of sales from affected injectable SKUs in July and most of August. With INR50 crore of combined sales in Q1, the company stated it had been tracking well to achieve an INR250 crore target for the year in the absence of the disruption. It now prefers to wait one more quarter before offering a revised FY27 objective, depending on how quickly lost SKUs regain market share.

Management also addressed concerns about market plateauing. It explained that early ramps in a category like semaglutide can include trial prescriptions and discontinuations, especially for injectables where side effects and patient suitability can drive drop-offs. It said it is already seeing market traction in July, and that oral formats appear to have lower drop-offs.

International: Brazil demand strong, Germany still difficult

Brazil performance showed a difference between underlying demand and reported primary sales. Based on internal sales, revenues were stated at BRL147 million (constant currency), with year-on-year growth discussed. The company also cited IQVIA data indicating Q1 market growth of 4% with Torrent growing at 19%, helped by performance of top brands and recent launches, including rosuvastatin ezetimibe.

At the same time, Torrent undertook a one-time channel inventory reduction. The channel had requested extended credit periods amid rising interest rates, and this action lowered primary sales relative to secondary sales. Management explicitly quantified what “normal” would have looked like, stating that without the channel inventory correction, constant currency sales would have grown by 15% to 18%. It expects growth to normalize back to mid-teens.

The US generics business recorded $44 million constant currency revenue, up 23%, driven by new launches where target market share was achieved as well as some one-time opportunities. Germany, in contrast, saw EUR29 million constant currency revenue, down 9%, impacted by supply disruption at a third-party supplier and lower tender off-take.

Management’s commentary on Germany was candid. It said a prominent supplier contributing 10% to 15% of revenue has been out of business, and that despite ongoing cost optimization, Torrent still finds itself outbid in tender processes. The message was that Germany is not yet out of the woods.

Takeaways: strong base, fast synergies, but watch integration and supply execution

Torrent’s Q1 FY27 reflected what investors typically look for after a large acquisition: stable growth, quick early synergy capture, and a clear operating plan for integration. Management believes double-digit growth for JB’s India Rx business for FY27 is still possible, and suggested high single-digit to low double-digit constant currency growth for the JB international business over the full year.

Two execution items now matter most in the near term. The first is ensuring brand and division transfers between JB and Torrent in India are handled smoothly, limiting the expected transient impact during the next 2 to 3 quarters. The second is restoring full semaglutide injectable availability by end-August and monitoring how quickly market share rebounds.

On leverage, the combined net debt to EBITDA was disclosed at 2.07x on underlying combined EBITDA. Management also indicated it would prefer not to exceed about 3x to 3.5x for future opportunities, while prioritising India-first if similar acquisition options exist.

Overall, Q1 FY27 reinforced that the combined Torrent-JB platform is operating from a position of strength. The quarter also showed that even with strong execution, near-term disruptions can emerge in high-growth categories. How quickly the integration phase stabilises and how effectively the semaglutide supply gap is closed will set the tone for the rest of FY27.